IMMX 8-K SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

IMMX ▲ +5.01% at T+5d

SHORT call ✗ call lost -5.01% · α vs SPY -3.35% · entry $8.78 → $9.22

Next anchor: T+20d in 12d

Currently $8.24 · +6.15% from $8.78 entry (call sign-flipped)

Entry anchored
May 21, 2026
via day open

T+1d

+0.68%

call -0.68% · α -0.10%

$8.84

settled 19d ago

T+5d

+5.01%

call -5.01% · α -3.35%

$9.22

settled 12d ago

T+20d

—

call — · α —

—

in 12d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Immix Biopharma priced an underwritten offering of 16,778,524 shares at $8.94 per share, raising $150M in gross proceeds (~$140.65M net). This massively dilutive event increases shares outstanding by roughly 31% (based on a ~$486M market cap at $20.57 pre-offering, implying ~23.6M shares pre-offering). Proceeds will fund NXC-201 CAR-T development and extend cash runway into mid-2028.

Actionable Insight

Immediate sell pressure expected from the massive share overhang. Watch for a possible price gap down on opening as the new shares hit the market. The extended cash runway into mid-2028 is a positive for the NXC-201 pipeline, but the dilution magnitude will dominate near-term price action. Monitor for any secondary offering or warrant registration cascade in the coming weeks.

Key Facts

16,778,524 shares offered at $8.94 per share for gross proceeds of $150M
Net proceeds estimated at ~$140.65M after underwriting discounts and expenses
Underwriters include Morgan Stanley (lead), BofA, LifeSci Capital, Mizuho, Needham
Shares sold at $8.4036 per share to underwriters (6% discount from public price)
90-day lock-up agreements on officers and directors
Proceeds to fund NXC-201 CAR-T development and extend cash runway into mid-2028
Net dilution of ~31% to existing shareholders based on share count implied by market cap

Financial Impact

$150M gross / ~$140.65M net proceeds raised via 16.78M share offering at $8.94/share; dilution ~31% to pre-offering float

share countdilutioncash runway

Risk Factors

Immediate dilution of ~31% will pressure stock price
Potential for follow-on offerings as shelf registration remains available
Clinical trial risk for NXC-201 could be amplified given larger share base
Underwriters may have overallotment option (not specified but typical) adding further dilution

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

90% bullish (10 analysts)

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-024872
Exhibit: ex5-1.htm	0001493152-26-024872
Exhibit: ex99-1.htm	0001493152-26-024872
Document: form8-k.htm	0001493152-26-024872
Document: 0001493152-26-024872-index-headers.html	0001493152-26-024872
Document: 0001493152-26-024872-index.html	0001493152-26-024872
Document: 0001493152-26-024872.txt	0001493152-26-024872

2 reports for IMMX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for IMMX — sortable, filterable
	Type				Now
May 21, 2026 19d ago	8-K BEARISH ★ 7/10	$8.78 $9.22	▼ −5.01%	▼ −3.35%	$8.24 (+6.15%)
May 21, 2026 20d ago	Press Release BULLISH ★ 8/10	$8.67 $9.00	▲ +3.81%	▲ +1.96%	$8.24 (−4.96%)

US Market Status

Market Open — Closes in 1h 3m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access